Back in 2007 and early 2008, Intercytex genuinely believed that good news was around the corner. This was based on the very promising results of the laboratory work. What happened was that the positive results of clinical trials were not as efficient as the lab ones. In other words although promising and exciting, not quite good enough to justify applying for a therapeutic product for the public. Since then three things have happened. Firstly the credit crunch hit the biotech sector hard in that major investors pulled out. Secondly, an unrelated Intercytex product did not come up with the goods, which meant negatively affecting the company share price. Thirdly, money aside, Intercytex agreed that the future probably lies in their ongoing lab research of making fully formed hairs from the cloned cells before taking them back to the donor. At this point, I dont know when this work will result in a clinical trial.
» from the internet
»
»
» Back in 2007 and early 2008, Intercytex genuinely believed that good news
» was around the corner. This was based on the very promising results of the
» laboratory work. What happened was that the positive results of clinical
» trials were not as efficient as the lab ones. In other words although
» promising and exciting, not quite good enough to justify applying for a
» therapeutic product for the public. Since then three things have happened.
» Firstly the credit crunch hit the biotech sector hard in that major
» investors pulled out. Secondly, an unrelated Intercytex product did not
» come up with the goods, which meant negatively affecting the company share
» price. Thirdly, money aside, Intercytex agreed that the future probably
» lies in their ongoing lab research of making fully formed hairs from the
» cloned cells before taking them back to the donor. At this point, I dont
» know when this work will result in a clinical trial.
» » from baldingblog.com
» »
» »
» » Back in 2007 and early 2008, Intercytex genuinely believed that good
» news
» » was around the corner. This was based on the very promising results of
» the
» » laboratory work. What happened was that the positive results of
» clinical
» » trials were not as efficient as the lab ones. In other words although
» » promising and exciting, not quite good enough to justify applying for a
» » therapeutic product for the public. Since then three things have
» happened.
» » Firstly the credit crunch hit the biotech sector hard in that major
» » investors pulled out. Secondly, an unrelated Intercytex product did not
» » come up with the goods, which meant negatively affecting the company
» share
» » price. Thirdly, money aside, Intercytex agreed that the future probably
» » lies in their ongoing lab research of making fully formed hairs from
» the
» » cloned cells before taking them back to the donor. At this point, I
» dont
» » know when this work will result in a clinical trial.
»
»
» Look!
» Hair follicle neogenesis induced by cultured human scalp dermal papilla cells - PubMed
» Is it a good news?
That’s an interesting link. Can someone break down what they’re saying in maybe more basic English?
Creating fully formed hairs from the cloned cells and then transplanting them in like a regular hair transplant always seemed to make more sense to me.
“promising” and “exciting” are cheap words.
Don’t blame the credit crunch MR. Farjo. ICX PRO doesn’t work. You completed Phase III, and it didn’t work. The credit crunch has nothing to do with this.
That is why ICX sank to the depths.
Basically, ICX put all of its money to ICX.PRO. The other products in the pipeline were fancy products just for show, with no allocated resources, because all your hopes were with PRO.
If PRO, the most cherished product, didn’t work, its not difficult to imagine how poor Vavelta and TRC, and others, perform.
So I think, the failure lies on fundamental flaws of the scientific team’s ideas.
And the idea of creating protohairs is not new. Many years ago, other doctors were already promising “hairs on a petri dish”. And still nothing. Old hypes with new envelopes.
We have already paid too much attention to this company. Now its Dr. Washenik’s time. Lets see how it goes.
» from baldingblog.com
»
»
» Back in 2007 and early 2008, Intercytex genuinely believed that good news
» was around the corner. This was based on the very promising results of the
» laboratory work. What happened was that the positive results of clinical
» trials were not as efficient as the lab ones. In other words although
» promising and exciting, not quite good enough to justify applying for a
» therapeutic product for the public. Since then three things have happened.
» Firstly the credit crunch hit the biotech sector hard in that major
» investors pulled out. Secondly, an unrelated Intercytex product did not
» come up with the goods, which meant negatively affecting the company share
» price. Thirdly, money aside, Intercytex agreed that the future probably
» lies in their ongoing lab research of making fully formed hairs from the
» cloned cells before taking them back to the donor. At this point, I dont
» know when this work will result in a clinical trial.
This is an advertising site for paid
advertisers to showcase successful hair restoration results only. It is not the
mandate of this site to engage in the discussion of failed, unsuccessful
procedures, lawsuits, litigations, refunds or complaint cases. Surgical hair
restoration procedures carry risks. Please do thorough research, consult your
own physician and investigate a doctor's background carefully before making a
decision. By proceeding to use our site, you agree to abide by our Terms of Use & Privacy Policy at http://hairsite.com/terms-of-use/ where you can also find a list of HairSite's sponsoring physicians.